Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 2/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.44 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | KDM5C | P41229 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5556374 | 0.98 | CHRM5 (0.47) | CHRM5CHRM3HSD17B10SIGMAR1SLC6A9 | |
| SCHEMBL472190 | 0.98 | CHRM5 (0.50) | CHRM5CHRM3HSD17B10SIGMAR1CXCR4 | |
| Piperazine SCHEMBL28199664 | 0.98 | CHRM5 (0.50) | CHRM5CHRM3HSD17B10SIGMAR1CXCR4 | |
| SCHEMBL934786 | 0.98 | CHRM5 (0.50) | CHRM5CHRM3HSD17B10SIGMAR1CXCR4 | |
| SCHEMBL29299554 | 0.98 | CHRM5 (0.50) | CHRM5CHRM3HSD17B10SIGMAR1SLC6A9 | |
| SCHEMBL306395 | 0.98 | CHRM5 (0.50) | CHRM5CHRM3HSD17B10SIGMAR1SLC6A9 | |
| SCHEMBL472213 | 0.98 | CHRM5 (0.50) | CHRM5CHRM3HSD17B10SIGMAR1SLC6A9 | |
| SCHEMBL8038178 | 0.95 | CHRM5 (0.48) | CHRM5CHRM3HSD17B10SIGMAR1SLC6A9 | |
| SCHEMBL6537424 | 0.95 | CHRM5 (0.48) | CHRM5CHRM3HSD17B10SIGMAR1SLC6A9 | |
| Hydrochloric Acid SCHEMBL28968883 | 0.95 | CHRM5 (0.48) | CHRM5CHRM3HSD17B10SIGMAR1SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1045838-B1 | 1,4,7,10-TETRAAZACYCLODODECANE-1,4-DIACETIC ACID | BRACCO IMAGING SPA (IT) | 2007-02-28 | — | — | EP | claimed |
| EP-1047677-B1 | Process for the preparation of derivatives of 1,4,7,10-tetraazacyclododecane-1,4-diacetic acid | BRACCO SPA (IT) | 2005-07-20 | — | — | EP | claimed |
| US-6342597-B1 | CONDENSATION REACTION TRIETHYLENETETRAMINE WITH GLYOXAL TO CYCLIZE; OXIDATION, ALKYLATION, HYDROLYSIS, QUATERNIZATION; NUCLEAR MAGNETIC RESONANCE IMAGING | DIBRA S.P.A. (IT) | 2002-01-29 | — | — | US | claimed |
| EP-1047677-A2 | Process for the preparation of derivatives of 1,4,7,10-tetraazacyclododecane-1,4-diacetic acid | BRACCO S.p.A. (IT) | 2000-11-02 | — | — | EP | claimed |
| EP-1045838-A1 | 1,4,7,10-TETRAAZACYCLODODECANE-1,4-DIACETIC ACID | BRACCO S.p.A. (IT) | 2000-10-25 | — | — | EP | claimed |
| WO-1999035134-A1 | 1,4,7,10-TETRAAZACYCLODODECANE-1,4-DIACETIC ACID | BRACCO S.P.A. (IT) | 1999-07-15 | — | — | WO | claimed |
| WO-1999035133-A2 | 1,4,7,10-TETRAAZACYCLODODECANE-1,4-DIACETIC ACID DERIVATIVES AS CHELATING AGENTS | BRACCO S.P.A. (IT) | 1999-07-15 | — | — | WO | claimed |
| US-12134610-B2 | Somatostatin subtype-2 receptor (SST2R) targeted therapeutics and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2024-11-05 | — | — | US | disclosed |
| EP-4455159-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS WITH BIO-DISTRIBUTION MODIFIER | 3B Pharmaceuticals GmbH (DE) | 2024-10-30 | — | — | EP | disclosed |
| US-20240254106-A1 | SOMATOSTATIN SUBTYPE-2 RECEPTOR (SST2R) TARGETED THERAPEUTICS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2024-08-01 | — | — | US | disclosed |
| US-20240254105-A1 | SOMATOSTATIN SUBTYPE-2 RECEPTOR (SST2R) TARGETED THERAPEUTICS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2024-08-01 | — | — | US | disclosed |
| US-10960088-B2 | Macrocycles, cobalt and iron complexes of same, and methods of making and using same | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2021-03-30 | — | — | US | disclosed |
| US-20160228581-A1 | MACROCYCLES, COBALT AND IRON COMPLEXES OF SAME, AND METHODS OF MAKING AND USING SAME | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2016-08-11 | — | — | US | disclosed |
| US-5977353-A | 1,4,7,10-tetraazabicyclo[8.2.2]tetradecan-2-one, a process for the preparation thereof and the use thereof for the preparation of tetraazamacrocycles | DIBRA S.P.A. (IT) | 1999-11-02 | — | — | US | disclosed |
| WO-1999035133-A3 | 1,4,7,10-TETRAAZACYCLODODECANE-1,4-DIACETIC ACID DERIVATIVES AS CHELATING AGENTS | BRACCO SPA (IT) | 1999-08-26 | — | — | WO | disclosed |
| WO-1999035134-A1 | 1,4,7,10-TETRAAZACYCLODODECANE-1,4-DIACETIC ACID | BRACCO S.P.A. (IT) | 1999-07-15 | — | — | WO | disclosed |
| WO-1999035134-A1 | 1,4,7,10-TETRAAZACYCLODODECANE-1,4-DIACETIC ACID | BRACCO S.P.A. (IT) | 1999-07-15 | — | — | WO | disclosed |
| WO-1999035134-A1 | 1,4,7,10-TETRAAZACYCLODODECANE-1,4-DIACETIC ACID | BRACCO S.P.A. (IT) | 1999-07-15 | — | — | WO | disclosed |
| WO-1999035133-A2 | 1,4,7,10-TETRAAZACYCLODODECANE-1,4-DIACETIC ACID DERIVATIVES AS CHELATING AGENTS | BRACCO S.P.A. (IT) | 1999-07-15 | — | — | WO | disclosed |
| WO-1999035133-A2 | 1,4,7,10-TETRAAZACYCLODODECANE-1,4-DIACETIC ACID DERIVATIVES AS CHELATING AGENTS | BRACCO S.P.A. (IT) | 1999-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12134610-B2 | Somatostatin subtype-2 receptor (SST2R) targeted therapeutics and uses thereof | SSTR2, SSTR1, SSTR4 | CHRM5 4496/4885CHRM3 3575/4885HSD17B10 3261/4885 |
| US-20240254106-A1 | SOMATOSTATIN SUBTYPE-2 RECEPTOR (SST2R) TARGETED THERAPEUTICS AND USES THEREOF | SSTR2, SSTR1, SSTR4 | CHRM5 4496/4885CHRM3 3575/4885HSD17B10 3261/4885 |
| US-20160228581-A1 | MACROCYCLES, COBALT AND IRON COMPLEXES OF SAME, AND METHODS OF MAKING AND USING SAME | ABCB7, FECH, CYC1 | CHRM5 4264/4885CHRM3 3717/4885HSD17B10 886/4885 |
| US-20240254105-A1 | SOMATOSTATIN SUBTYPE-2 RECEPTOR (SST2R) TARGETED THERAPEUTICS AND USES THEREOF | SSTR2, SSTR1, SSTR4 | CHRM5 4496/4885CHRM3 3575/4885HSD17B10 3261/4885 |
| US-10960088-B2 | Macrocycles, cobalt and iron complexes of same, and methods of making and using same | ABCB7, FECH, CYC1 | CHRM5 4264/4885CHRM3 3717/4885HSD17B10 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.